You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News and reporting on cancer immunotherapy.
PGDx has the exclusive rights to develop both tissue- and blood-based diagnostics using MSK’s TMB-related intellectual property.
BMS amended an ongoing Phase III study of Opdivo and Yervoy to evaluate outcomes based on tumor mutational burden using Foundation Medicine's NGS companion diagnostic.
Over the next three years, the company and its partners will assess the OneRNA platform to diagnose bladder cancer, select treatment, and measure response and recurrence.
The company believes it can overcome its challenges, and highlighted strong continued interest from pharma despite a disappointing end to its Merck deal.
The researchers plan to add the MSI detection capabilities to an NGS panel and will use the information to guide cancer patients to precision medicine trials.
The company is developing a test based on computational quantitation of a subtype cells called MDSCs, which play a role in the tumor microenvironment.
New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.
The collaborations will evaluate whether patient-specific ex vivo cancer immunotherapy assays can predict in vivo efficacy, and ACEA's cell analysis platform.
The belief among genomics experts that one day drugs would be given based on genomic abnormalities that cut across tumor types became reality this week.
In a milestone for the cancer community, the agency approved Keytruda for the genomic features of a cancer, not where the tumor occurs in the body.